CoAResearch-gradepeptides,documented tothe milligram.
Every vial is HPLC-verified, lot-traceable, and shipped with a third-party Certificate of Analysis. No proprietary blends. No mystery excipients. Just the compound, documented.
Every vial passes inspection.
Tested, ships today.
Every compound here has a signed certificate from ILS Laboratories, open on its product page.
CoA
CoA
CoA
CoA
CoA
CoAThe archive — 21 entries,
each reproducible.
Every compound below is maintained as a live monograph. Open an entry for synthesis route, stability data, the full CoA, and buffer-compatibility notes.
BPC-157
Gastric pentadecapeptide. Synthesised and freeze-dried under inert argon.
BPC-157
PentadecapeptideTB-500
Actin-sequestering peptide fragment. Lyophilised, sealed at 18 °C.
TB-500
Thymosin fragmentGHK-Cu
Endogenous tripeptide–copper complex. Royal blue lyophilisate.
GHK-Cu
Copper tripeptideSemax
Synthetic analogue of ACTH(4-10). Sequence conserved from the endogenous ACTH fragment.
Semax
ACTH analogueSelank
Tuftsin analogue. Stored at −20 °C; thaw once only.
Selank
Tuftsin analogueTesamorelin
Stabilised 44-residue peptide analogue. Amber glass, N₂ headspace.
Tesamorelin
Peptide analogueMOTS-c
16-residue peptide encoded within the mitochondrial 12S rRNA region.
MOTS-c
Mitochondrial peptideReconstitution Solution
Sterile solution for reconstituting lyophilised material. 0.9% benzyl alcohol.
Reconstitution Solution
DiluentWolverine
Co-lyophilised blend of BPC-157 and TB-500 in a single vial.
Wolverine
Peptide blendCJC-1295 Ipamorelin
CJC-1295 (no-DAC) paired with Ipamorelin. Co-lyophilised.
CJC-1295 Ipamorelin
Peptide blendRetatrutide
GLP-1 / GIP / glucagon triple receptor agonist. Lyophilised.
Retatrutide
Tri-agonistTirzepatide
GLP-1 / GIP dual receptor agonist. Lyophilised.
Tirzepatide
Dual agonistGLOW 70
Multi-peptide blend. 70 mg total.
GLOW 70
Peptide blendIpamorelin
Selective synthetic pentapeptide. Lyophilised.
Ipamorelin
PentapeptideKPV
C-terminal tripeptide of α-MSH. Lyophilised.
KPV
α-MSH fragmentMazdutide
GLP-1 / glucagon dual receptor agonist. Lyophilised.
Mazdutide
Dual agonist5-Amino-1MQ
5-amino-1-methylquinolinium iodide. NNMT inhibitor.
5-Amino-1MQ
Small moleculeGlutathione
Reduced glutathione (GSH). 1.5 g per vial.
Glutathione
Thiol tripeptidePT-141
Melanocortin receptor agonist. Cyclic heptapeptide.
PT-141
Melanocortin agonistIGF-1 LR3
Long Arg3 insulin-like growth factor 1 analogue.
IGF-1 LR3
IGF analogueMelanotan 2
Cyclic α-MSH analogue. Lyophilised.
Melanotan 2
Melanocortin agonistSix stepsbetween the residueand the vial.
We publish our synthesis protocol because reproducibility is the only credential that matters. Every batch is retained and reassayed for five years.
- Retention
- 5 yr
- Retest cycle
- 90 d
- Cleanroom
- ISO 7
- Endotoxin
- <0.1
- I
Synthesis
≤ 24 hrper compoundSolid-phase Fmoc synthesis on Rink Amide resin. Coupled in DMF with HBTU activation.
- II
Cleavage & precipitation
−20 °CetherolysisTFA / TIPS / water cocktail; crude peptide precipitated in cold diethyl ether.
- III
Purification
≥ 99.0%purity floorReverse-phase HPLC on C18 column; acetonitrile / water / 0.1% TFA gradient.
- IV
Assay
3×independent labsMass-spec confirmation (ESI-TOF), endotoxin LAL assay, residual solvent GC.
- V
Fill & finish
ISO 7cleanroomFiltered through 0.22 µm into amber borosilicate, argon-flushed, capped and crimped.
- VI
Lyophilisation
−50 °Cprimary dryFreeze-drying at −50 °C under 0.01 mbar for 36 hrs; residual moisture < 1%.
We don't sell wellness.
We sell a receipt.
One compound per vial. Anything else is theatre.
Open CoAs. Open synthesis route. Open lot numbers.
For research use only. We will not pretend otherwise.















